Avalo Therapeutics, Inc. (AVTX)
After hours:
| Previous Close | 15.90 |
| Open | 15.58 |
| Bid | 14.01 x 300 |
| Ask | 14.35 x 100 |
| Day's Range | 13.15 - 16.00 |
| 52 Week Range | 3.95 - 1,130.40 |
| Volume | |
| Avg. Volume | 692,581 |
| Market Cap | 14.85M |
| Beta (5Y Monthly) | 1.17 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -114.00 |
| Earnings Date | May 06, 2024 - May 10, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 35.00 |
GlobeNewswireAvalo Therapeutics Appoints Biotech Leaders to Board of Directors
Appointments include industry veterans Aaron Kantoff, Jonathan Goldman, and Samantha Truex as Independent DirectorsBoard of Director appointments in conjunction with Avalo’s recent acquisition of AVTX-009, an anti-IL-1β mAb, and up to $185 million private placement financing WAYNE, Pa. and ROCKVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced the addition of multiple biotech leaders to its Board of Directors. The Avalo Board brings together a
- GlobeNewswire
Avalo Reports 2023 Financial Results and Provides Business Updates
Acquired AVTX-009, Phase-2 ready anti-IL-1β mAb, in March 2024Increased cash position with private placement financing in March 2024 providing up to $185 million, including initial upfront investment of $115.6 millionTopline results from planned Phase 2 trial of AVTX-009 in hidradenitis suppurativa expected in 2026Expected cash runway into 2027 WAYNE, Pa. and ROCKVILLE, Md., March 29, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced business updates and year-end
- GlobeNewswire
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
Avalo acquires Phase 2-ready anti-IL-1β mAb, AVTX-009, through acquisition of AlmataBio, Inc. Topline results from planned Phase 2 trial in hidradenitis suppurativa expected in 2026Executed private placement financing of up to $185 million, including initial upfront investment of $115.6 million; expected to extend cash runway into 2027 Webcast to be held tomorrow, March 28, 2024 at 8:30 a.m. E.T. WAYNE, Pa. and ROCKVILLE, Md., March 27, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq:
